Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.

Mentors in Medicine Series on Applied Precision Medicine: Focus on How Far Novel Therapies Have Come in Hodgkin Lymphoma

Release Date: July 15, 2021
Expiration Date: July 15, 2022

Activity Overview

Mentors in Medicine Series on Applied Precision Medicine: Focus on How Far Novel Therapies Have Come in Hodgkin Lymphoma is a CME-certified, case-based, live webcast. This educational activity will provide practicing oncologists with expert perspectives on incorporating biomarker testing into everyday clinical practice to determine diagnosis and inform treatment selection for their patients with Hodgkin lymphoma. Renowned faculty will analyze recent clinical trial evidence to optimize therapeutic strategies, using real patient cases as a starting point. Each case will include an expert analysis of Show Me the Data® as well as Key Takeaways 4 Tomorrow that can be applied immediately in the oncology clinical practice.

This educational activity is an archive of the live virtual webcast held on July 8, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is intended for hematologists and oncologists involved in the treatment of patients with Hodgkin lymphoma. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of Hodgkin lymphoma are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Incorporate biomarker testing into diagnosis and/or therapy selection for the treatment of patients with Hodgkin lymphoma
  • Analyze recent data on the efficacy and safety of therapeutic options for the treatment of patients with Hodgkin lymphoma
  • Apply optimal management strategies in the treatment of patients with Hodgkin lymphoma based on recent clinical trial findings

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Series Chair

Andre Goy, MD
Andre Goy, MD
Physician-in-Chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer, John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology, Hackensack Meridian School of Medicine
Professor of Medicine, Georgetown University
Hackensack, NJ

Disclosures: Grant/Research Support: PI: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffmann-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen Pharmaceuticals, Karyopharm, Kite Pharma, Pharmacyclics; Consultant: Acerta Pharma, Celgene Corporation, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma, Xcenda; Stock/Shareholder: COTA; Other: Honoraria: AstraZeneca, Celgene Corporation, Gilead Sciences, Kite Pharma, Xcenda; Advisory: AstraZeneca, COTA, Elsevier’s PracticeUpdate, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma.


Tatyana Feldman, MD
Tatyana Feldman, MD
T-Cell Lymphoma Program
John Theurer Cancer Center Hackensack Meridian Health
Hackensack, NJ

Disclosures: Consultant/Advisory Board: AbbVie, ADC Therapeutics, AstraZeneca, Daiichi, Karyopharm, Kite Pharma, Kyowa Kirin, MorphoSys; Other: AbbVie, BMS, Celgene Corporation, Janssen Pharmaceuticals, Pharmacyclics, Seagen, Takeda.


Fredrick Hagemeister, MD
Fredrick Hagemeister, MD
Professor of Medicine
Department of Lymphoma/Myeloma
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX

Disclosures: Consultant: Genentech.

Alison Moskowitz, MD
Alison Moskowitz, MD
Associate Attending
Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: ADC Therapeutics, BeiGene Miragen, Seagen, Merck, Bristol Myers Squibb, Incyte; Consultant: Janpix Ltd., Merck, Seagen, Imbrium Therapeutics L.P./Purdue, Takeda.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By